The Effectiveness of Prophylactic Antibiotics for Urethral Bulking
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Tess Gao, MD
- Phone Number: 973-971-7267
- Email: tess.gao@atlantichealth.org
Study Locations
-
-
New Jersey
-
Morristown, New Jersey, United States, 07960
- Recruiting
- Atlantic Health
-
Contact:
- Tess Gao, MD
- Phone Number: 9739717267
- Email: tess.gao@atlantichealth.org
-
Contact:
- Erika Wasenda, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients scheduled to undergo a urethral bulking procedure
- Age 18 ≥ over
Exclusion Criteria:
- History of recurrent urinary tract infections
- Known history of urinary retention
- Allergies or contraindications to multiple antibiotics
- Inability to tolerate oral antibiotics
- Concomitant surgical procedures at the time of urethral bulking
- Pregnant or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Antibiotic Group
Those randomized to this group will receive a one-time dose of an oral antibiotic prior to the urethral bulking procedure.
The antibiotic will be based on the participants' allergies, medical history, and current medication list.
|
These participants will be given a single dose of an oral antibiotic prior to the procedure.
|
|
Other: No antibiotic group
Those randomized to this group will not receive an antibiotic prior to the urethral bulking procedure.
|
These participants will not be given an antibiotic prior to the procedure.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of urinary tract infection (UTI)
Time Frame: Within 4 weeks after the procedure
|
The rate of UTI based on symptoms and a positive urine culture
|
Within 4 weeks after the procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of postoperative urinary retention
Time Frame: Within 4 weeks after the procedure
|
The rate of postoperative urinary retention
|
Within 4 weeks after the procedure
|
|
Rates of other postoperative complications
Time Frame: Within 4 weeks after the procedure
|
The rate of other complications (bleeding, discomfort, etc)
|
Within 4 weeks after the procedure
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Erika Wasenda, MD, Atlantic Health System
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Male Urogenital Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urination Disorders
- Lower Urinary Tract Symptoms
- Urological Manifestations
- Infections
- Urinary Incontinence
- Urinary Incontinence, Stress
- Urinary Tract Infections
- Anti-Infective Agents
- Antitubercular Agents
- Anti-Bacterial Agents
- Antibiotics, Antitubercular
Other Study ID Numbers
Other Study ID Numbers
- 2107044-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.